Citations (82)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (20)
Claude Mékiès, Olivier Heinzlef, Béatrice Jenny, Anne-Laure Ramelli & Pierre Clavelou. (2018) Treatment satisfaction and quality of life in patients treated with fingolimod. Patient Preference and Adherence 12, pages 899-907.
Read now
Read now
Diana Ferraro, Valentina Camera, Eleonora Baldi, Veria Vacchiano, Erica Curti, Angelica Guareschi, Susanna Malagù, Sara Montepietra, Silvia Strumia, Mario Santangelo, Luisa Caniatti, Matteo Foschi, Alessandra Lugaresi, Franco Granella, Ilaria Pesci, Luisa Motti, Walter Neri, Paolo Immovilli, Enrico Montanari, Francesca Vitetta, Anna Maria Simone & Patrizia Sola. (2018) First-line disease-modifying drugs in relapsing–remitting multiple sclerosis: an Italian real-life multicenter study on persistence. Current Medical Research and Opinion 34:10, pages 1803-1807.
Read now
Read now
Dessalegn Y Melesse, Ruth Ann Marrie, James F Blanchard, Bo Nancy Yu & Charity Evans. (2017) Persistence to disease-modifying therapies for multiple sclerosis in a Canadian cohort. Patient Preference and Adherence 11, pages 1093-1101.
Read now
Read now
María Dolores Edo Solsona, Emilio Monte Boquet, Bonaventura Casanova Estruch & José Luis Poveda Andrés. (2017) Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by Rebismart® in patients with multiple sclerosis. Patient Preference and Adherence 11, pages 415-421.
Read now
Read now
Michael Munsell, Molly Frean, Joseph Menzin & Amy L Phillips. (2017) An evaluation of adherence in patients with multiple sclerosis newly initiating treatment with a self-injectable or an oral disease-modifying drug. Patient Preference and Adherence 11, pages 55-62.
Read now
Read now
Kendra L Furber, Marina Van Agten, Charity Evans, Azita Haddadi, J Ronald Doucette & Adil J Nazarali. (2017) Advances in the treatment of relapsing–remitting multiple sclerosis: the role of pegylated interferon β-1a. Degenerative Neurological and Neuromuscular Disease 7, pages 47-60.
Read now
Read now
Thomas R. Einarson, Basil G. Bereza & Márcio Machado. (2017) Comparative effectiveness of interferons in relapsing–remitting multiple sclerosis: a meta-analysis of real-world studies. Current Medical Research and Opinion 33:3, pages 579-593.
Read now
Read now
Peter Joseph Jongen, Wim A Lemmens, Raymond Hupperts, Erwin LJ Hoogervorst, Hans M Schrijver, Astrid Slettenaar, Els L de Schryver, Jan Boringa, Esther van Noort & Rogier Donders. (2016) Persistence and adherence in multiple sclerosis patients starting glatiramer acetate treatment: assessment of relationship with care received from multiple disciplines. Patient Preference and Adherence 10, pages 909-917.
Read now
Read now
Damiano Paolicelli, Eleonora Cocco, Valentina Di Lecce, Vita Direnzo, Lucia Moiola, Roberta Lanzillo, Paola Perini, Simona Malucchi, Giovanna Borriello, Emilio Portaccio, Valentina Panetta, Giuseppe Fenu, Francesca Sangalli, Laura Cacciaguerra & Maria Trojano. (2016) Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study. Expert Opinion on Drug Delivery 13:6, pages 799-805.
Read now
Read now
Antonios Bayas & Mathias Mäurer. (2015) Teriflunomide for the treatment of relapsing–remitting multiple sclerosis: patient preference and adherence. Patient Preference and Adherence 9, pages 265-274.
Read now
Read now
Marcello Moccia, Raffaele Palladino, Cinzia Russo, Marco Massarelli, Antonio Nardone, Maria Triassi, Alessandra Lugaresi & Vincenzo Brescia Morra. (2015) How many injections did you miss last month? A simple question to predict interferon β-1a adherence in multiple sclerosis. Expert Opinion on Drug Delivery 12:12, pages 1829-1835.
Read now
Read now
Sander Yermakov, Matthew Davis, Michaela Calnan, Monica Fay, Brieana Cox-Buckley, Sujata Sarda, Mei Sheng Duh & Ravi Iyer. (2015) Impact of increasing adherence to disease-modifying therapies on healthcare resource utilization and direct medical and indirect work loss costs for patients with multiple sclerosis. Journal of Medical Economics 18:9, pages 711-720.
Read now
Read now
Antonios Bayas, Jean Christophe Ouallet, Boris Kallmann, Raymond Hupperts, Ulrich Fulda & Kurt Marhardt. (2015) Adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study. Expert Opinion on Drug Delivery 12:8, pages 1239-1250.
Read now
Read now
Raymond Hupperts, Veit Becker, Janne Friedrich, Claudio Gobbi, Antonio Vasco Salgado, Bjørn Sperling & Xiaojun You. (2015) Multiple sclerosis patients treated with intramuscular IFN-β-1a autoinjector in a real-world setting: prospective evaluation of treatment persistence, adherence, quality of life and satisfaction. Expert Opinion on Drug Delivery 12:1, pages 15-25.
Read now
Read now
Mark Cascione, Daniel Wynn, Luigi M. Barbato, Linda Pestreich, Lesley Schofield & Kevin McCague. (2013) Randomized, open-label study to evaluate patient-reported outcomes with fingolimod after changing from prior disease-modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design. Journal of Medical Economics 16:7, pages 859-865.
Read now
Read now
MerriKay Oleen-Burkey, Anissa Cyhaniuk & Eric Swallow. (2013) Treatment patterns in multiple sclerosis: administrative claims analysis over 10 years. Journal of Medical Economics 16:3, pages 397-406.
Read now
Read now
J. I. Ivanova, R. E. Bergman, H. G. Birnbaum, A. L. Phillips, M. Stewart & D. M. Meletiche. (2012) Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US. Journal of Medical Economics 15:3, pages 601-609.
Read now
Read now
Rachel Halpern, Sonalee Agarwal, Carole Dembek, Leigh Borton & Maria Lopez-Bresnahan. (2011) Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis. Patient Preference and Adherence 5, pages 73-84.
Read now
Read now
Krithika Rajagopalan, Richard A. Brook, Ian A. Beren & Nathan L. Kleinman. (2011) Comparing costs and absences for multiple sclerosis among US employees: pre- and post-treatment initiation. Current Medical Research and Opinion 27:1, pages 179-188.
Read now
Read now
Nathan L. Kleinman, Ian A. Beren, Krithika Rajagopalan & Richard A. Brook. (2010) Medication adherence with disease modifying treatments for multiple sclerosis among US employees. Journal of Medical Economics 13:4, pages 633-640.
Read now
Read now
Articles from other publishers (62)
Aliza Bitton Ben-Zacharia, Bryan Walker, Amy Perrin Ross, Carlo Tornatore, Natalie C. Edwards, Yvette Lipman & Amy L. Phillips. (2023) Factors Associated With Disease-Modifying Therapy Adherence and Persistence in Multiple Sclerosis: A Scoping Literature Review. International Journal of MS Care 25:5, pages 188-195.
Crossref
Crossref
Elizabeth S. Gromisch, Aaron P. Turner, Steven L. Leipertz, John Beauvais & Jodie K. Haselkorn. (2022) Demographic and Clinical Factors Are Associated With Frequent Short-Notice Cancellations in Veterans With Multiple Sclerosis on Disease Modifying Therapies. Archives of Physical Medicine and Rehabilitation 103:5, pages 915-920.e1.
Crossref
Crossref
Francesca Washington & Dawn Langdon. (2021) Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review. Journal of Neurology 269:4, pages 1861-1872.
Crossref
Crossref
Anthony T Reder, Nancy Arndt, Cortnee Roman, Caroline Geremakis, Jason P Mendoza, Ray Su, Charles Makin, Robin L Avila & Megan C Vignos. (2021) Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders 51, pages 102935.
Crossref
Crossref
Sanni Lahdenperä, Merja Soilu‐Hänninen, Hanna‐Maija Kuusisto, Sari Atula, Jouni Junnila & Anders Berglund. (2020) Medication adherence/persistence among patients with active multiple sclerosis in Finland. Acta Neurologica Scandinavica 142:6, pages 605-612.
Crossref
Crossref
Kathiaja Miranda Souza, Isabela Maia Diniz, Lívia Lovato Pires de Lemos, Nélio Gomes Ribeiro Junior, Isabella de Figueiredo Zuppo, Juliana Alvares Teodoro, Francisco de Assis Acurcio, Álvaro Nagib Atallah & Augusto Afonso Guerra Júnior. (2020) Effectiveness of first-line treatment for relapsing-remitting multiple sclerosis in Brazil: A 16-year non-concurrent cohort study. PLOS ONE 15:9, pages e0238476.
Crossref
Crossref
Elizabeth S. Gromisch, Aaron P. Turner, Steven L. Leipertz, John Beauvais & Jodie K. Haselkorn. (2020) Risk Factors for Suboptimal Medication Adherence in Persons With Multiple Sclerosis: Development of an Electronic Health Record-Based Explanatory Model for Disease-Modifying Therapy Use. Archives of Physical Medicine and Rehabilitation 101:5, pages 807-814.
Crossref
Crossref
Sergio Sauri-Suárez, Sandra Quiñones-Aguilar, Arturo Contreras-Marín, Erik Omar Ramiro-Guerrero, David Zúñiga-García, Leticia Salinas-Vázquez, Leonardo Llamas-López, Carolina León-Jiménez, Adriana García-Martell, Iliana González-Hernández, Erwin Chiquete & Silvia García. (2020) Adherence to self-administering interferon-β1a using RebiSmart® device in Mexican patients with relapsing multiple sclerosis. PLOS ONE 15:4, pages e0230959.
Crossref
Crossref
Pengxiang Li, Vrushabh P. Ladage, Joseph Berger, Salim Chahin, Mehul Jhaveri, Caroline Geremakis & Jalpa A. Doshi. (2020) Disease-Modifying Therapy Adherence and Associated Factors in a National Sample of Medicare Patients With Multiple Sclerosis. Value in Health 23:3, pages 328-334.
Crossref
Crossref
Elizabeth S. Gromisch, Aaron P. Turner, Steven L. Leipertz, John Beauvais & Jodie K. Haselkorn. (2020) Who is not coming to clinic? A predictive model of excessive missed appointments in persons with multiple sclerosis. Multiple Sclerosis and Related Disorders 38, pages 101513.
Crossref
Crossref
Nick Bansback, Judy A. Chiu, Robert Carruthers, Rebecca Metcalfe, Emmanuelle Lapointe, Alice Schabas, Marilyn Lenzen, Larry D. Lynd & Anthony Traboulsee. (2019) Development and usability testing of a patient decision aid for newly diagnosed relapsing multiple sclerosis patients. BMC Neurology 19:1.
Crossref
Crossref
Maciej Wilski, Piotr Kocur, Mirosław Górny, Magdalena Koper, Anna Nadolska, Bartosz Chmielewski & Maciej Tomczak. (2019) Perception of Multiple Sclerosis Impact and Treatment Efficacy Beliefs: Mediating Effect of Patient's Illness and Self-Appraisals. Journal of Pain and Symptom Management 58:3, pages 437-444.
Crossref
Crossref
David P. Jarmolowicz, Derek D. Reed, Amanda S. Bruce & Jared M. Bruce. (2019) On the behavioral economics of medication choice: A research story. Behavioural Processes 165, pages 66-77.
Crossref
Crossref
Jonathan Lim, Carl Samuelsen, Amanda Golembesky, Sulena Shrestha, Li Wang & Ingolf Griebsch. (2019) Duration of treatment among patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive non-small-cell lung cancer in the USA. Future Oncology 15:13, pages 1493-1504.
Crossref
Crossref
Christine Lebrun-Frenay, Antoine Moulignier, Charles Pierrot-Deseilligny, Rabah Benrabah, Thibault Moreau, Catherine Lubetzki & Françoise Monchecourt. (2019) Five-year outcome in the copaxone observatory: a nationwide cohort of patients with multiple sclerosis starting treatment with glatiramer acetate in France. Journal of Neurology 266:4, pages 888-901.
Crossref
Crossref
Emma Bartolomé-García, Ángela Usarralde-Pérez, Patricia Sanmartín-Fenollera & Monserrat Pérez-Encinas. (2019) Persistence and adherence to interferon and glatiramer acetate in patients with multiple sclerosis. European Journal of Hospital Pharmacy 26:1, pages 23-28.
Crossref
Crossref
Jared M. Bruce, Amanda S. Bruce, Sharon Lynch, Joanie Thelen, Seung-Lark Lim, Julia Smith, Delwyn Catley, Derek D. Reed & David P. Jarmolowicz. (2018) Probability discounting of treatment decisions in multiple sclerosis: associations with disease knowledge, neuropsychiatric status, and adherence. Psychopharmacology 235:11, pages 3303-3313.
Crossref
Crossref
SivaNaga S. Anumolu, Sam Lindgren, Janardhana Vemula, David Floch, Christine Reynolds, Hans‐Joachim Wallny & Haiying Sun. (2018) Bioequivalence of Canakinumab Injected Subcutaneously via an Autoinjector Device or a Prefilled Safety Syringe Device in Healthy Subjects. Clinical Pharmacology in Drug Development 7:8, pages 829-836.
Crossref
Crossref
Pengxiang Li, Tianyan Hu, Xinyan Yu, Salim Chahin, Nabila Dahodwala, Marissa Blum, Amy R. Pettit & Jalpa A. Doshi. (2018) Impact of Cost-Sharing Increases on Continuity of Specialty Drug Use: A Quasi-Experimental Study. Health Services Research 53, pages 2735-2757.
Crossref
Crossref
Jay Visaria, Nina Thomas, Tao Gu, Joseph Singer & Hiangkiat Tan. (2018) Understanding the Patient's Journey in the Diagnosis and Treatment of Multiple Sclerosis in Clinical Practice. Clinical Therapeutics 40:6, pages 926-939.
Crossref
Crossref
Joanie Thelen, Amanda Bruce, Delwyn Catley, Sharon Lynch, Kathy Goggin, Andrea Bradley-Ewing, Morgan Glusman, Abigail Norouzinia, Lauren Strober & Jared Bruce. (2017) Baseline predictors of DMT reinitiation among patients with multiple sclerosis following an MI–CBT intervention. Journal of Behavioral Medicine 41:2, pages 253-260.
Crossref
Crossref
Oscar Fernández, Eduardo Duran, Teresa Ayuso, Luis Hernández, Inmaculada Bonaventura & Mireia Forner. (2017) Treatment satisfaction with injectable disease-modifying therapies in patients with relapsing-remitting multiple sclerosis (the STICK study). PLOS ONE 12:10, pages e0185766.
Crossref
Crossref
Kristen M. JohnsonHuanxue ZhouFeng LinJohn J. KoVivian Herrera. (2017) Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year. Journal of Managed Care & Specialty Pharmacy 23:8, pages 844-852.
Crossref
Crossref
Luca Degli Esposti, Carlo Piccinni, Diego Sangiorgi, Valentina Perrone, Lucia Aledda, Maria Giovanna Marrosu & Fabio Lombardo. (2017) Changes in first-line injectable disease-modifying therapy for multiple sclerosis: predictors of non-adherence, switching, discontinuation, and interruption of drugs. Neurological Sciences 38:4, pages 589-594.
Crossref
Crossref
J Nicholas, JJ Ko, Y Park, P Navaratnam, HS Friedman, FR Ernst & V Herrera. (2017) Assessment of treatment patterns associated with injectable disease-modifying therapy among relapsing–remitting multiple sclerosis patients. Multiple Sclerosis Journal - Experimental, Translational and Clinical 3:1, pages 205521731769611.
Crossref
Crossref
Barry Hendin, DeRen Huang, Sibyl Wray, Robert T Naismith, Sheri Rosenblatt, Javier Zambrano & Brian Werneburg. (2017) Subcutaneous peginterferon β-1a injection-site reaction experience and mitigation: Delphi analysis of the ALLOW study. Neurodegenerative Disease Management 7:1, pages 39-47.
Crossref
Crossref
Virginia A. Devonshire, Anthony Feinstein & Patrick Moriarty. (2016) Adherence to interferon β-1a therapy using an electronic self-injector in multiple sclerosis: a multicentre, single-arm, observational, phase IV study. BMC Research Notes 9:1.
Crossref
Crossref
Antonia Csillik, Jared Bruce, Delwyn Catley, Marie-Claire Gay, Kathleen J Goggin, Keri R Swaggart, Peter W Thomas & Sarah Thomas. (2016) Psychological interventions for enhancing adherence to disease-modifying therapies (DMTs) in multiple sclerosis. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Marcello Moccia, Raffaele Palladino, Antonio Carotenuto, Cinzia Valeria Russo, Maria Triassi, Roberta Lanzillo & Vincenzo Brescia Morra. (2016) Predictors of long-term interferon discontinuation in newly diagnosed relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders 10, pages 90-96.
Crossref
Crossref
Inês Correia, Inês Brás Marques, Mário Sousa, Sónia Batista, Rogério Ferreira, Carla Nunes, Carmo Macário, Luís Cunha & Lívia Sousa. (2016) Predictors of first-line treatment persistence in a Portuguese cohort of relapsing-remitting multiple sclerosis. Journal of Clinical Neuroscience 33, pages 73-78.
Crossref
Crossref
Charity Evans, Ruth Ann Marrie, Feng Zhu, Stella Leung, Xinya Lu, Dessalegn Y. Melesse, Elaine Kingwell, Yinshan Zhao & Helen Tremlett. (2016) Adherence and persistence to drug therapies for multiple sclerosis: A population-based study. Multiple Sclerosis and Related Disorders 8, pages 78-85.
Crossref
Crossref
Matthew Warrender-Sparkes, Tim Spelman, Guillermo Izquierdo, Maria Trojano, Alessandra Lugaresi, François Grand’Maison, Eva Havrdova, Dana Horakova, Cavit Boz, Celia Oreja-Guevara, Raed Alroughani, Gerardo Iuliano, Pierre Duquette, Marc Girard, Murat Terzi, Raymond Hupperts, Pierre Grammond, Thor Petersen, Ricardo Fernandez-Bolaños, Marcela Fiol, Eugenio Pucci, Jeannette Lechner-Scott, Freek Verheul, Edgardo Cristiano, Vincent Van Pesch, Tatjana Petkovska-Boskova, Fraser Moore, Ilya Kister, Roberto Bergamaschi, Maria Laura Saladino, Mark Slee, Michael Barnett, Maria Pia Amato, Cameron Shaw, Neil Shuey, Carolyn Young, Orla Gray, Ludwig Kappos, Helmut Butzkueven, Tomas Kalincik & Vilija Jokubaitis. (2015) The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. Multiple Sclerosis Journal 22:4, pages 520-532.
Crossref
Crossref
Jared M. Bruce, Amanda S. Bruce, Delwyn Catley, Sharon Lynch, Kathleen Goggin, Derek Reed, Seung-Lark Lim, Lauren Strober, Morgan Glusman, Abigail R. Ness & David P. Jarmolowicz. (2015) Being Kind to Your Future Self: Probability Discounting of Health Decision-Making. Annals of Behavioral Medicine 50:2, pages 297-309.
Crossref
Crossref
Jared Bruce, Amanda Bruce, Sharon Lynch, Lauren Strober, Sean O’Bryan, Deborah Sobotka, Joan Thelen, Abigail Ness, Morgan Glusman, Kathy Goggin, Andrea Bradley-Ewing & Delwyn Catley. (2015) A pilot study to improve adherence among MS patients who discontinue treatment against medical advice. Journal of Behavioral Medicine 39:2, pages 276-287.
Crossref
Crossref
Kerstin Hansen, Katrin Schüssel, Marita Kieble, Johanna Werning, Martin Schulz, Robert Friis, Dieter Pöhlau, Norbert Schmitz & Joachim Kugler. (2015) Adherence to Disease Modifying Drugs among Patients with Multiple Sclerosis in Germany: A Retrospective Cohort Study. PLOS ONE 10:7, pages e0133279.
Crossref
Crossref
A. Saiz, S. Mora & J. Blanco. (2015) Treatment compliance with first line disease-modifying therapies in patients with multiple sclerosis. COMPLIANCE Study. Neurología (English Edition) 30:4, pages 214-222.
Crossref
Crossref
A. Saiz, S. Mora & J. Blanco. (2015) Cumplimiento terapéutico con terapias modificadoras de la enfermedad de primera línea en pacientes con esclerosis múltiple. Estudio COMPLIANCE. Neurología 30:4, pages 214-222.
Crossref
Crossref
Simon Zhornitsky, Jamie Greenfield, Marcus W. Koch, Scott B. Patten, Colleen Harris, Winona Wall, Katayoun Alikhani, Jodie Burton, Kevin Busche, Fiona Costello, Jeptha W. Davenport, Scott E. Jarvis, Dina Lavarato, Helene Parpal, David G. Patry, Michael Yeung & Luanne M. Metz. (2015) Long-Term Persistence with Injectable Therapy in Relapsing-Remitting Multiple Sclerosis: An 18-Year Observational Cohort Study. PLOS ONE 10:4, pages e0123824.
Crossref
Crossref
MerriKay Oleen-Burkey, Anissa Cyhaniuk & Eric Swallow. (2014) Retrospective US database analysis of persistence with glatiramer acetate vs. available disease-modifying therapies for multiple sclerosis: 2001–2010. BMC Neurology 14:1.
Crossref
Crossref
Raymond Hupperts, Lizette Ghazi-Visser, Ana Martins Silva, Michalis Arvanitis, Hanna Kuusisto, Kurt Marhardt & Nikolaos Vlaikidis. (2014) The STAR Study: A Real-World, International, Observational Study of the Safety and Tolerability of, and Adherence to, Serum-Free Subcutaneous Interferon β-1a in Patients With Relapsing Multiple Sclerosis. Clinical Therapeutics 36:12, pages 1946-1957.
Crossref
Crossref
Barbara Teter, Neetu Agashivala, Katelyn Kavak, Lynn Chouhfeh, Ron Hashmonay & Bianca Weinstock-Guttman. (2013) Characteristics influencing therapy switch behavior after suboptimal response to first-line treatment in patients with multiple sclerosis. Multiple Sclerosis Journal 20:7, pages 830-836.
Crossref
Crossref
B.O. Khatri, J. Pelletier, L. Kappos, H.-P. Hartung, G. Comi, F. Barkhof, P. von Rosenstiel, X. Meng, A. Grinspan, R. Hashmonay & J.A. Cohen. (2014) Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing–Remitting Multiple Sclerosis (TRANSFORMS). Multiple Sclerosis and Related Disorders 3:3, pages 355-363.
Crossref
Crossref
Marcelo Kremenchutzky, Paul O’Connor, Reinhard Hohlfeld, Lixin Zhang-Auberson, Philipp von Rosenstiel, Xiangyi Meng, Augusto Grinspan, Ron Hashmonay & Ludwig Kappos. (2014) Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Multiple Sclerosis and Related Disorders 3:3, pages 341-349.
Crossref
Crossref
Anne Howley & Marcelo Kremenchutzky. (2014) Pegylated Interferons. Journal of Neuroscience Nursing 46:2, pages 88-96.
Crossref
Crossref
Luca Prosperini, Chiara Rosa Mancinelli, Carlo Pozzilli, Maria Grazia Grasso, Alessandro Clemenzi, Sara Collorone, Simona Pontecorvo, Ada Francia, Veronica Villani, Tatiana Koudriavtseva, Fabio Buttari, Diego Centonze, Giancarlo Di Battista, Giovanni Frisullo, Simonetta Galgani & Claudio Gasperini. (2014) From High- to Low-Frequency Administered Interferon-Beta for Multiple Sclerosis: A Multicenter Study. European Neurology 71:5-6, pages 233-241.
Crossref
Crossref
Robert J. Fox, Amber R. Salter, Tuula Tyry, Jennifer Sun, Xiaojun You, Genevieve Laforet & Denise Campagnolo. (2013) Treatment Discontinuation and Disease Progression with Injectable Disease-Modifying Therapies. International Journal of MS Care 15:4, pages 194-201.
Crossref
Crossref
Ana Ožura, Lea Kovač & Saša Šega. (2013) Adherence to disease-modifying therapies and attitudes regarding disease in patients with multiple sclerosis. Clinical Neurology and Neurosurgery 115, pages S6-S11.
Crossref
Crossref
Machaon M. Bonafede, Barbara H Johnson, Madé Wenten & Crystal Watson. (2013) Treatment Patterns in Disease-Modifying Therapy for Patients With Multiple Sclerosis in the United States. Clinical Therapeutics 35:10, pages 1501-1512.
Crossref
Crossref
Gina Remington, Yolanda Rodriguez, Diana Logan, Caroline Williamson & Katherine Treadaway. (2013) Facilitating Medication Adherence in Patients with Multiple Sclerosis. International Journal of MS Care 15:1, pages 36-45.
Crossref
Crossref
Aaron E Miller. (2013) The best clinical paper on multiple sclerosis in 2012. Multiple Sclerosis Journal 19:5, pages 520-521.
Crossref
Crossref
Vilija G. Jokubaitis, Tim Spelman, Jeannette Lechner-Scott, Michael Barnett, Cameron Shaw, Steve Vucic, Danny Liew, Helmut Butzkueven, Mark Slee & on behalf of the Australian MSBase Study Group. (2013) The Australian Multiple Sclerosis (MS) Immunotherapy Study: A Prospective, Multicentre Study of Drug Utilisation Using the MSBase Platform. PLoS ONE 8:3, pages e59694.
Crossref
Crossref
N. Grytten, J. H. Aarseth, K. Espeset, G. B. Johnsen, R. Wehus, C. Lund & R. C. Haugstad. (2013) Stoppers and non-starters of disease-modifying treatment in multiple sclerosis. Acta Neurologica Scandinavica 127:2, pages 133-140.
Crossref
Crossref
Robert J Fox. (2013) In the coming year we should abandon interferons and glatiramer acetate as first-line therapy for MS: Yes. Multiple Sclerosis Journal 19:1, pages 24-25.
Crossref
Crossref
Alessandra Lugaresi, Ciro Florio, Vincenzo Brescia-Morra, Salvatore Cottone, Paolo Bellantonio, Marinella Clerico, Diego Centonze, Antonio Uccelli, Maria di Ioia, Giovanna De Luca, Andrea Marcellusi & Andrea Paolillo. (2012) Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study. BMC Neurology 12:1.
Crossref
Crossref
Claire Meyniel, Timothy Spelman, Vilija G. Jokubaitis, Maria Trojano, Guillermo Izquierdo, François Grand’Maison, Celia Oreja-Guevara, Cavit Boz, Alessandra Lugaresi, Marc Girard, Pierre Grammond, Gerardo Iuliano, Marcela Fiol, Jose Antonio Cabrera-Gomez, Ricardo Fernandez-Bolanos, Giorgio Giuliani, Jeannette Lechner-Scott, Edgardo Cristiano, Joseph Herbert, Tatjana Petkovska-Boskova, Roberto Bergamaschi, Vincent van Pesch, Fraser Moore, Norbert Vella, Mark Slee, Vetere Santiago, Michael Barnett, Eva Havrdova, Carolyn Young, Carmen-Adella Sirbu, Mary Tanner, Michelle Rutherford & Helmut Butzkueven. (2012) Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. PLoS ONE 7:6, pages e38661.
Crossref
Crossref
Oscar Fernández, Javier Agüera, Guillermo Izquierdo, Javier Millán-Pascual, Lluis Ramió i Torrentà, Pedro Oliva, Javier Argente, Yasmina Berdei, Jose Maria Soler, Olga Carmona, Jose Maria Errea & Jordi Farrés. (2012) Adherence to Interferon β-1b Treatment in Patients with Multiple Sclerosis in Spain. PLoS ONE 7:5, pages e35600.
Crossref
Crossref
R. Santolaya Perrín, M. Fernández-Pacheco García Valdecasas, L. Arteche Eguizabal, I. Gema Pérez Pérez, N. Muñoz Muñoz, O. Ibarra Barrueta & G. Callejón Callejón. (2012) Adherencia subóptima al tratamiento en la esclerosis múltiple. Farmacia Hospitalaria 36:3, pages 124-129.
Crossref
Crossref
Charity Evans, Jennifer Tam, Elaine Kingwell, Joel Oger & Helen Tremlett. (2012) Long-Term Persistence With the Immunomodulatory Drugs for Multiple Sclerosis: A Retrospective Database Study. Clinical Therapeutics 34:2, pages 341-350.
Crossref
Crossref
Mark Sanford & Katherine A. Lyseng-Williamson. (2011) Subcutaneous Recombinant Interferon-β-1a (Rebif®). Drugs 71:14, pages 1865-1891.
Crossref
Crossref
Rachel Halpern, Sonalee Agarwal, Leigh Borton, Kathy Oneacre & Maria V. Lopez-Bresnahan. (2011) Adherence and persistence among multiple sclerosis patients after one immunomodulatory therapy failure: Retrospective claims analysis. Advances in Therapy 28:9, pages 761-775.
Crossref
Crossref
Jared M. Bruce & Sharon G. Lynch. (2011) MS treatment adherence—how to keep patients on medication?. Nature Reviews Neurology 7:8, pages 421-422.
Crossref
Crossref
Janice Wong, Tara Gomes, Muhammad Mamdani, Michael Manno & Paul W. O'Connor. (2014) Adherence to Multiple Sclerosis Disease-Modifying Therapies in Ontario is Low. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 38:3, pages 429-433.
Crossref
Crossref